Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity

Fig. 7

CircMEMO1 Regulated the Antitumour Activity of Sorafenib Treatment in HCC Cells. a Overall survival curves were compared between HCC patients with a high or low TCF21 level treated with sorafenib in TCGA database. b Comparison of overall survival curves between 40 advanced-stage recurrent HCC patients receiving combined sorafenib and TACE treatment who underwent liver resection before combined therapy. c MTT assays were used to detect the growth of Huh-7 and HCCLM3 cells with different circMEMO1 levels treated with sorafenib. d Matrigel invasion assays were used to investigate the migration ability of HCC cells with different circMEMO1 levels treated with sorafenib. e, f Overall survival curves were compared between recurrent HCC patients with a high or low circMEMO1 or miR-106b-5p level treated with sorafenib. g Schematic depiction of the mechanisms underlying circMEMO1 regulating HCC progression via the miR-106b-5p/TET1/5hmC axis

Back to article page

Molecular Cancer

ISSN: 1476-4598